Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post-hoc analysis of the AWARD-4 study across baseline body mass index subgroups.

Aims: Insulin-treated patients with type 2 diabetes (T2D) and obesity are challenged in achieving body weight stability or reduction, in addition to glycaemic control. Post-hoc analyses of body weight and insulin dose data from the AWARD-4 trial involved comparison of treatment with once-weekly dulaglutide 1.5 mg (N = 295) or 0.

[A new combination therapy for diabetic gastroparesis].

According to our knowledge and for the first time we refer about the combination therapy with gastric electric stimulation and injection of botulinus toxin into the pylorus at a patient with increased symptomatic diabetic gastroparesis for the first time. The prospectively documented gastroparesis-symptom-score improved dramatically under this combination therapy, while time of gastric emptying of 50 % (specified by scintigraphy) was showing solely a low decrease. 18 months after beginning the combination therapy its positive effect is to be watched furthermore, complications haven't occurred yet.